Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | Nasdaq debutante Septerna swells its IPO to $331m | 2 | pharmaphorum | ||
Mi | Septerna, Inc.: Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering | 24 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral... ► Artikel lesen | |
Mi | IPO Radar: Septerna, Swiggy and Horizon Robotics | 4 | The Armchair Trader | ||
28.10. | Septerna verzeichnet Aktienkäufe im Wert von 11,7 Millionen US-Dollar durch Third Rock Ventures | 4 | Investing.com Deutsch | ||
28.10. | Septerna, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
28.10. | IPO Roundup: Brazil Potash, Septerna and more | 3 | Seeking Alpha | ||
25.10. | Septerna, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
25.10. | Septerna's Upsized IPO Brings In $288M to Support a Pipeline of GPCR Drugs | 2 | MedCity News | ||
25.10. | Biotech firm Septerna jumps in Nasdaq debut | 1 | Reuters | ||
25.10. | Septerna Shares Jump 42% After IPO Shows Biotech Still Hot | 2 | BNN Bloomberg | ||
25.10. | Septerna valued at $970 million as shares rise nearly 31% in Nasdaq debut | - | Reuters | ||
25.10. | Septerna's $288M IPO is another sign of the market warming to biotech investment | 4 | FierceBiotech | ||
25.10. | GPCR-focused biotech Septerna prices further upsized IPO at $18 | 3 | Renaissance Capital | ||
25.10. | GPCR drugmaker Septerna amasses $288M in IPO | 7 | BioPharma Dive | ||
25.10. | Septerna Prices IPO Of 16.00 Mln Shares At $18.00/shr | 3 | RTTNews | ||
25.10. | Septerna, Inc.: Septerna Prices Upsized Initial Public Offering | 285 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral... ► Artikel lesen | |
24.10. | GPCR-focused biotech Septerna ups proposed deal size by 57% ahead of $275 million IPO | 3 | Renaissance Capital | ||
24.10. | Goldman-backed drug developer Septerna targets $743 million valuation in upsized US IPO | 3 | Reuters | ||
22.10. | Septerna, Inc. - 8-A12B, Registration of securities | 1 | SEC Filings | ||
21.10. | Septerna plans $158M IPO to fund clinical readouts for GPCR pipeline | 1 | FierceBiotech |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 8,100 | +13,37 % | Evotec-Aktie: Shortseller schwitzen mächtig | Wenige Tage vor den mit Hochspannung erwarteten neuen Zahlen drückt die Evotec-Aktie (WKN: 566480) mächtig aufs Gaspedal. Zum Wochenstart hat sie um fast +9% zugelegt, auf Tradegate ging es sogar um... ► Artikel lesen | |
QIAGEN | 40,170 | +1,11 % | QIAGEN N.V.: QIAGEN erhält FDA-Zulassung für QIAstat-Dx Mini-Panel für eine präzisere ambulante Behandlung von Atemwegserkrankungen | QIAstat-Dx Respiratory Panel Mini erkennt die fünf relevantesten Erreger von Atemwegserkrankungen im ambulanten Bereich und hilft Ärzten dabei, präzise Behandlungsentscheidungen zu treffen // Mithilfe... ► Artikel lesen | |
VIKING THERAPEUTICS | 57,96 | -0,17 % | Nach Kursvervierfachung: Viking Therapeutics: "Großartiger" Test bei Adipositas-Pille - Aktie explodiert! | Die Aktie von Viking Therapeutics haussiert am Montag um 26 Prozent, nachdem eine klinische Studie mit seiner experimentellen oralen Gewichtsabnahmepille vielversprechende Ergebnisse gezeigt hat.Eine... ► Artikel lesen | |
ADMA BIOLOGICS | 19,120 | 0,00 % | ADMA Biologics, Inc. (NASDAQ:ADMA) Holdings Increased by Roman Butler Fullerton & Co. | ||
BIONTECH | 102,20 | -0,20 % | Biontech-Partner top in Q3: Pfizer übertrifft Erwartungen und hebt Jahresprognose an | © Foto: Foto: Nicolas Maeterlinck/ - BELGA/dpaPfizer hat starke Ergebnisse für das dritte Quartal präsentiert, die sowohl beim Umsatz als auch beim bereinigten Gewinn deutlich über den Analystenschätzungen... ► Artikel lesen | |
DISC MEDICINE | 58,19 | 0,00 % | Disc Medicine Inc: Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval | Alignment with the FDA across all proposed study parameters, providing a clear development path to registrationAgreement on proposed primary endpoint of average monthly time in sunlight during the... ► Artikel lesen | |
LONGBOARD PHARMACEUTICALS | 59,52 | 0,00 % | Longboard Pharmaceuticals, Inc.: Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline | The proposed acquisition represents a significant step forward in Lundbeck's Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 44,820 | +6,46 % | Avidity Biosciences target held at $59 by Goldman Sachs | ||
SUMMIT THERAPEUTICS | 19,980 | 0,00 % | Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024 | MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reported an update on its operational progress and financial results for the third quarter... ► Artikel lesen | |
HARMONY BIOSCIENCES | 33,075 | -0,14 % | Harmony Biosciences Reports Strong Third Quarter 2024 Financial Results And Highlights Catalyst-rich, Late-stage Pipeline Poised To Deliver One Or More New Launches Every Year Over Next Five Years | WAKIX (pitolisant) Net Revenue of $186.0 Million for Third Quarter 2024; Surpassed $2B in Cumulative Net Revenue in Less Than Five Years
On Track to Submit sNDA... ► Artikel lesen | |
ARCELLX | 86,46 | +0,99 % | Arcellx (ACLX) Surged in Q3. Here's Why | ||
BEAM THERAPEUTICS | 24,340 | +6,75 % | Beam Therapeutics Q3 2024 Earnings Preview | ||
DYNE THERAPEUTICS | 28,780 | 0,00 % | Dyne Therapeutics Reports Positive Data From Phase 1/2 DELIVER Trial Of DYNE-251 In DMD | WASHINGTON (dpa-AFX) - Tuesday, Dyne Therapeutics, Inc. (DYN) revealed new clinical findings from its Phase 1/2 DELIVER trial of DYNE-251 for patients with Duchenne muscular dystrophy also known... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 6,620 | 0,00 % | Peering Into Recursion Pharmaceuticals' Recent Short Interest | ||
IMMUNOVANT | 29,435 | 0,00 % | Immunovant Inc.: Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting |